Fetal hemoglobin in various forms of childhood leukemia. Relation to relapse and remission

Detection of acquired hemoglobinopathy in children with hematological malignancies at disease onset: results form a national referral centre

Abnormal hemoglobin synthesis is usually inherited but may also arise as a secondary manifestation of a hematological neoplasia. The objective of this study is to identify the presence of acquired hemoglobinopathy in children diagnosed with hematological malignancies and compare these against healthy controls. Prospective matched case-control study held from 2010 to 2012. For each patient with hematological malignancy two healthy controls matched on gender, age and race were recruited. Patients with other co-morbidities were excluded. All samples underwent supravital staining and high-performance liquid chromatography (HPLC) electrophoresis. Following identification of abnormal results, molecular genetic testing for all α- and β-thalassemia mutations prevalent in the Greek population was performed. Other causes of anemia were ruled out based on specific testing. A total of 44 (32 males) patients with a mean age of 7.1 years were enrolled in the study. Hematological disorders included acute lymphocytic leukemia (24), acute myeloid leukemia (8), non-Hodgkin lymphoma (8), Hodgkin disease (3), and Langerhans cell histiocytosis (1). Following exclusion of congenital hemoglobinopathies, atypical HPLC electrophoretic findings persisted in 18.1 % of the patient group, compared to 0 % in the control group (p < 0.001). The patient group showed marked microcytic anemia (p < 0.01) and detection of small inclusions (p = 0.034) on supravital staining. Comparison of the HPLC findings between the groups demonstrated significantly lower percentages of HbA (p = 0.02), normal HbA2 and higher percentage of fast moving Hb bands (p = 0.04) in the patient group. Interestingly, the majority of these patients belonged to the high-risk group. Acquired hemoglobinopathy is recognized in adult patients. This is a novel study describing evidence of abnormal erythropoiesis in children with hematological malignancies and in particular those classified as high-risk cancer patients according to international criteria.

Initial blood fetal hemoglobin concentration is elevated and is associated wtih prognosis in children with acute lymphoid or myeloid leukemia

We examined the relationship between initial blood fetal hemoglobin (HbF) concentration and prognosis in 100 children with leukemia. HbF concentration was usually elevated and ranged between 0 and 19.5 g/l. Multivariate analysis showed that, in patients with acute lymphoblastic leukemia (ALL), each increment of 1 g/l in initial HbF concentration resulted in a 1.13-fold rise in the risk of death or relapse (95% confidence limits 1.01-1.25, P less than 0.05). In patients with myeloid leukemias, each increment of 1 g/l in HbF was associated with a 1.20-fold (1.05-1.37, P less than 0.02) rise in the risk of death or relapse. In the patients with myeloid leukemias the mean initial HbF concentration was also higher (3.4 g/l; 0.5-19.5 g/l) than in the patients with ALL (1.1 g/l; 0-18.7 g/l; P = 0.08). Our results indicate that the degree of increase in HbF synthesis is associated with the degree of malignancy: the more aggressive the disease, the more augmented is the synthesis of HbF.

Globin chain synthesis in a case of acquired aplastic anaemia before and after remission induced by bolus methylprednisolone treatment

Globin chain synthesis was performed with the peripheral blood of a 10-year-old girl, who had acquired aplastic anaemia, at the time of bolus methylprednisolone administration and during recovery. There was no indication of an increase in gamma chain synthesis despite elevation of total foetal haemoglobin.

The patterns of fetal haemoglobin production in leukaemia

Elevated levels of haemoglobin F (Hb F) have been foudn in a wide range of haematological malignancies, but very high levels were found only in juvenile chronic myeloid leukaemia (JCML), and erythroleukaemia occurring in infancy. In both these disorders a reversion to a fetal form of erythropoiesis may occur, as judged by both the structure of the Hb F and by the disappearance of Hb A2 and the carbnoic-anhydrase isozymes during the course of the illness. The clinical picture of JCML is not always associated with a reversion to fetal erythropoiesis; there appears to be a heterogeneity of conditions with this clinical label. Thus the reversion to a completely fetal pattern of erythropoiesis seems to occur in a variety of leukaemias which start in early life. This change is associated with a uniformly bad prognosis. Of a group of 17 patients with acute myeloid leukaemia 15 developed an increase in the level of Hb F about 60 days after the commencement of treatment; significantly greater increases were observed in those achieving a clinical remission. The level of Hb F usually declined during remission but high levels persisted in a few cases. Increased levels of Hb F were found also in patients with other haematological malignancies who had undergone periods of marrow aplasia during treatment. In all cases the Hb F was heterogeneously distributed throughout the red cells. Analysis of gamma15 or gammaCB3 peptides of Hb F from a variety of leukaemias gave glycine compositions ranging from 0.20 to 0.85 residues with many values in the fetal range; all cases with a reversion to fetal erythropoiesis had values in the fetal range. Attempts to confirm the 'fetal' origin of the cells containing Hb F by means of other markers was possible only in the cases of JCML and in one child with erythroleukaemia. These studies indicate that in some forms of leukaemia there may be a genuine reversion to fetal erythropoiesis while in others the emergence of cells containing Hb F appears to be part of a rapid regeneration process occurring after a period of marrow aplasia. The diagnostic and prognostic value of these observations is discussed.